Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With COVID-19
  2. OPTIMISE: Reduced Antihypertensive Meds in Older Patients
  3. Variation in False-Negative Rate of RT-PCR–Based SARS-CoV-2 Tests by Time Since Exposure
  4. Triple Combination of Interferon Beta-1b, Lopinavir–Ritonavir, and Ribavirin in the Treatment of Patients Admitted to the Hospital With COVID-19
  5. Use of SGLT2 Inhibitors and Risk of Serious Renal Events
  6. SARS-Cov-2 Interaction With the Renin-Angiotensin System
  7. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome
  8. COVID-19 and Renin–Angiotensin Blockers
  9. COVID-19 and the Implications for the Cardiovascular System
  10. Dapagliflozin Reduces Risk of Worsening Heart Failure or Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Most Read This Week

Recently Updated